Introduction
Organised cancer screening programmes are a cornerstone of cancer control in the European Union. Cancer screening is a strategic priority for the European Commission, which has set ambitious targets for coverage and quality as part of its cancer control agenda. The CanScreen-ECIS pilot project, followed by the CanScreen5 Europe initiative and the 3rd EU Implementation Report, aims to provide a harmonised assessment of screening programmes maturity, coverage, and quality across the 27 EU Member States.
Methods
Data were collected using standardised CanScreen-ECIS and CanScreen5 tools, mapping “essential” and “desirable” elements of programme organisation, governance, service delivery, information systems, and quality assurance. Country submissions were reviewed for completeness and consistency, and results were synthesised into country factsheets and regional benchmarks.
Results
Breast cancer screening: All 27 Member States have established population-based programmes, supported by dedicated budgets in 64%. They typically target women aged 45–74 years, offering biennial mammography. Active invitation systems are present in 96% and referral pathways are documented in 80% of the programmes.
Cervical cancer screening: Population-based programmes have been implemented in 21/27 member states, supported by dedicated budgets in 64%. Programs are increasingly adopting HPV-based screening, offered every 5 years in the age range 30 to 64. Active invitation systems are present in 85% and referral pathways are documented in 80% of the programmes.
Colorectal cancer screening: Programmes, mainly offering biennial FIT, in the age range 50 to 74, have been implemented in 26/27 member states, supported by dedicated budgets in 71%.. Programme maturity varies, with 3 countries piloting or scaling up. Active invitation systems are present in 91% and referral pathways are documented in 71% of the programmes
Lung cancer screening: No Member State has a fully organised national programme; activity is limited to pilots, research, or feasibility studies. All of them are offering screening with spiral CTAcross all cancers, the mapping reveals strengths in programme endorsement and coverage, but highlights persistent gaps in the implementation of referral pathways for assessment and treatment, IT systems supporting monitoring, linkage to cancer registries, and routine performance audits.
Conclusions
The CanScreen-ECIS pilot and CanScreen5 platform, together with the 3rd EU Implementation Report, provide a comprehensive, harmonised overview of cancer screening implementation in the EU. While progress is evident, especially for breast, cervical, and colorectal screening, further efforts are needed to strengthen information systems, quality assurance, and registry integration, and to advance lung cancer screening. The forthcoming EU-GAINS project will further facilitate the documentation of the current status and enable global monitoring of quantitative and qualitative data about the performance of cancer screening programs at the EU level. Importantly, all these data will be integrated into the ECIS platform at the Joint Research Centre (JRC), ensuring accessibility and supporting evidence-based policy-making and continued improvement of cancer screening programmes across Europe